Last updated: July 27, 2026
Pfizer Inc. v. Aurobindo Pharma Limited (E.D. Texas, No. 1:23-cv-00923) is a generic-entry patent infringement case filed in 2023 by Pfizer against Aurobindo. The docket number identifies the matter, but the case record content (asserted patents, asserted claims, counts, remedies, and procedural posture such as Teva/Aurobindo settlement, injunction, or trial schedule) is not provided in the input. Without the docket text and pleadings, a complete, accurate litigation summary cannot be produced.
What is Pfizer Inc. v. Aurobindo Pharma Limited (1:23-cv-00923) about?
Answer: The input confirms the case name, parties, court jurisdiction (implied by “1:23-cv-00923”), and docket number, but does not provide the asserted drug, Orange Book reference product, or patent numbers asserted.
What claims and patents are typically at issue in Pfizer vs. Aurobindo generic cases?
In generic entry litigation in the U.S., the typical structure includes:
- Paragraph IV patent infringement claims tied to an ANDA
- Potential method-of-use and formulation patents depending on the reference listed drug
- Relief seeking injunction against commercial launch and damages
The specific asserted patents and claims in this matter are not included in the provided information.
Which patents does Pfizer assert against Aurobindo in case 1:23-cv-00923?
Answer: Not determinable from the provided input.
How to identify the asserted patent list
A complete answer requires docket documents such as the complaint and infringement contentions, including:
- Asserted U.S. patent numbers
- Claim chart references
- Any later-conformed claims list after amendments
Those details are not present.
What is the procedural posture of Pfizer v. Aurobindo (1:23-cv-00923)?
Answer: Not determinable from the provided input.
Key milestones that must be sourced from the docket
A litigation summary normally covers:
- Complaint filing date
- Motions practice (MTRs, transfer requests, dismissal motions)
- Claim construction (Markman) schedule
- Trial date and any stay status (common in Hatch-Waxman cases)
- Final judgment or settlement if entered
No docket timeline is supplied.
Has this Pfizer v. Aurobindo case settled, and what does that mean for generic launch timing?
Answer: Not determinable from the provided input.
If there is a settlement, what terms matter
For business and infringement risk, settlement terms typically include:
- “Launch at risk” carve-outs
- Design-around obligations or non-infringement licenses
- Confidential market allocation or supply restrictions
- Dismissal language and dismissal dates tied to exclusivity windows
None of these facts are provided.
What is the Orange Book status for the patents-in-suit in Pfizer v. Aurobindo?
Answer: Not determinable from the provided input.
Orange Book inputs needed for an accurate status map
A correct Orange Book analysis requires:
- The reference listed drug (RLD) name and NDA/BLA
- Listed patents and their expiration dates
- Whether patents are NDC-specific
- Any pediatric exclusivity or patent term adjustments affecting timelines
Those inputs are not included.
What is the infringement theory: ANDA Paragraph IV, method-of-use, or formulation protection?
Answer: Not determinable from the provided input.
Typical Pfizer infringement theories in generic actions
Without pleadings, the litigation “theory” cannot be pinned down. Common categories include:
- Active-ingredient structure and composition claims
- Manufacturing or process claims
- Formulation claims (e.g., sustained release matrices, particle size ranges)
- Method-of-use claims (when Pfizer owns a patient-population or dosing regimen patent)
No claim categories are provided.
How strong is Pfizer’s patent estate versus Aurobindo’s likely defenses?
Answer: Not determinable from the provided input.
What defense angles must be evaluated
A credible strength analysis requires:
- Claim construction outcomes
- Infringement elements tied to the ANDA product
- Invalidity defenses (35 U.S.C. §§ 102/103/112), enablement, written description
- Prior art and secondary considerations, if relevant
- Expert report positions and technology tutorial record
None of these sources are present in the input.
What is Aurobindo’s likely risk profile for injunctions and damages in 1:23-cv-00923?
Answer: Not determinable from the provided input.
Injunction exposure depends on
- Likely likelihood of success post-Markman
- Whether Pfizer seeks and obtains an injunction (often via settlement, consent, or final judgment)
- The court’s handling of confidentiality and claim construction
- Whether the case is stayed pending related proceedings
No procedural facts are provided.
Which companies are co-defendants or related parties in this case?
Answer: Not determinable from the provided input.
Why co-defendants matter
Co-defendants can change:
- Indemnity structure
- Manufacturing responsibility
- Venue transfer risk
- Settlement dynamics
No caption details beyond “Pfizer Inc. v. Aurobindo Pharma Limited” are supplied.
Key Takeaways
- The input identifies the docket number (1:23-cv-00923) and the named parties, but does not provide the complaint, patent list, procedural posture, claim construction outcomes, or settlement/disposition documents.
- A complete litigation summary and analysis cannot be produced without those record elements.
FAQs
- What is the drug and ANDA number tied to Pfizer Inc. v. Aurobindo Pharma Limited (1:23-cv-00923)?
- Which specific Pfizer patents are listed as “patents-in-suit” in 1:23-cv-00923?
- What is the Markman schedule and claim construction status in Pfizer v. Aurobindo (1:23-cv-00923)?
- Did the parties enter a settlement in Pfizer v. Aurobindo (1:23-cv-00923), and did it trigger a stipulated dismissal?
- What is the Orange Book RLD and expiration date risk if Aurobindo launches before a noninfringement ruling?
References (APA)
- Case caption and docket number provided in prompt: Pfizer Inc. v. Aurobindo Pharma Limited, 1:23-cv-00923.
